Skip to main content
Livermore
Livermore
中文EN

Damora Therapeutics, Inc.

DMRA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001800315

In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.68B in total; Viking Global Investors is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Damora Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $7.35K in total
Insiders trading
1
Net value
−$7.35K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Damora Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Damora Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Cheng AndrewDirector–Aug 13, 20261
Winslow GarrettGeneral Counsel2,289Jul 7, 20263
Jarrett JenniferSee Remarks500,000Apr 1, 20261
Harwin Peter EvanDirector, 10% Owner2,904,000IndirectMar 25, 20262
Fairmount Healthcare Fund II L.P.Director, 10% Owner2,904,000IndirectMar 25, 20262
Fairmount Funds Management LLCDirector, 10% Owner2,904,000IndirectMar 25, 20262
Kiselak Tomas10% Owner2,904,000IndirectMar 25, 20262
Fairmount Healthcare Co-Invest V L.P.Director, 10% Owner2,904,000IndirectMar 25, 20262
Landsittel MichaelDirector–Mar 25, 20261
Turtle CameronDirector–Mar 25, 20261
Cain Christopher W.Director–Mar 25, 20261
Bruno JulianneDirector137,032Mar 25, 20262
Sattarzadeh SherwinChief Operating Officer190,376Jan 26, 20261
Hewes L. BeckerChief Medical Officer264,629Jan 7, 20261
Firmani LoriChief Financial Officer931Jan 6, 20261
Schambye Hans T.Chief Executive Officer4,682Jan 6, 20261
Goldfischer CarlDirector–Jun 20, 20250
Shapiro DavidDirector–Jun 20, 20250
Munshi AmitDirector–Jun 20, 20250
Dallas Jayson Donald AlexanderDirector–Jun 20, 20250
Wechsler Amy BDirector–Jun 20, 20250
Prener AnneDirector–Jun 20, 20250
Kronmiller MatthewEVP Strategy and CBO–Jan 7, 20250
Freve JonathanChief Financial Officer12,000Jan 5, 20240
OrbiMed Advisors LLC10% Owner1,510,375IndirectAug 17, 20230
OrbiMed Israel GP II, L.P.10% Owner1,510,375IndirectAug 17, 20230
OrbiMed Advisors Israel II Ltd10% Owner1,510,375IndirectAug 17, 20230
OrbiMed Capital GP VII LLC10% Owner1,510,375IndirectAug 17, 20230
OrbiMed Genesis GP LLC10% Owner1,510,375IndirectAug 17, 20230
Khuong Chau QuangDirector–Jun 15, 20230
Lindmark BertilChief Medical Officer16,604Jan 5, 20230
Pedersen AndersChief Operating Officer–Jan 5, 20230
Oestreich StephanieChief Business Officer–Jan 5, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 7, 2026 (view filing)8:00 PM ETJul 61 dayWinslow GarrettGeneral CounselSSale−245$29.98−$7.35K−9.7%2.29K after
Jan 6, 2026 (view filing)Jan 24 daysSchambye Hans T.Chief Executive OfficerSSale−700$21.38−$15.0K−13.0%4.68K after
Jan 6, 2026 (view filing)Jan 24 daysWinslow GarrettGeneral CounselSSale−255$21.38−$5.45K−12.1%1.85K after
Jan 6, 2026 (view filing)Jan 24 daysFirmani LoriChief Financial OfficerSSale−135$21.41−$2.89K−12.7%931 after
Jul 8, 2025 (view filing)Jul 35 daysSchambye Hans T.Chief Executive OfficerSSale−735$3.38−$2.48K−15.5%4.02K after
Jul 8, 2025 (view filing)Jul 35 daysWinslow GarrettGeneral CounselSSale−260$3.39−$881.4−15.4%1.43K after
Jul 8, 2025 (view filing)Jul 35 daysFirmani LoriInterim CFOSSale−147$3.39−$498.33−17.5%692 after
Jan 7, 2025 (view filing)Jan 34 daysWinslow GarrettGeneral CounselSSale−471$5.60−$2.64K−31.8%1.01K after
Jan 7, 2025 (view filing)Jan 34 daysFirmani LoriInterim CFOSSale−261$5.63−$1.47K−36.0%465 after
Jan 7, 2025 (view filing)Jan 34 daysSchambye Hans T.Chief Executive OfficerSSale−1.34K$5.60−$7.51K−28.3%3.40K after
Aug 17, 2023 (view filing)4:40 PM ETAug 152 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−822.7K$0.75−$617.0K−35.3%1.51M after3 lots
Aug 2, 2023 (view filing)5:05 PM ETJul 312 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−209.4K$3.00−$628.2K−9.0%2.11M after3 lots
Jul 27, 2023 (view filing)4:28 PM ETJul 252 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−39.2K$2.92−$114.5K−1.7%2.26M after3 lots
Jul 17, 2023 (view filing)4:13 PM ETJul 134 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−194.7K$2.40−$467.3K−7.8%2.29M after3 lots
Apr 17, 2023 (view filing)5:28 PM ETApr 13-174 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−68.5K$1.87−$128.3K−2.8%2.42M after9 lots
Apr 12, 2023 (view filing)6:44 PM ETApr 10-122 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−67.5K$1.80−$121.4K−2.7%2.46M after9 lots
Apr 7, 2023 (view filing)4:42 PM ETApr 5-62 daysOrbiMed Advisors LLC and 4 others10% OwnerSSale−102.6K$2.16−$222.0K−3.9%2.51M after6 lots
Mar 23, 2022 (view filing)Mar 221 dayLindmark BertilChief Medical OfficerPPurchase+14.6K$2.16+$31.5K+730.2%16.6K after
Mar 23, 2022 (view filing)Mar 221 daySchambye Hans T.Chief Executive OfficerPPurchase+5.00K$2.15+$10.8K+10.5%52.4K after
Dec 6, 2021 (view filing)Dec 33 daysWinslow GarrettGeneral CounselPPurchase+2.00K$2.48+$4.96K+100.0%4.00K after
Dec 6, 2021 (view filing)Dec 33 daysFreve JonathanChief Financial OfficerPPurchase+4.00K$2.49+$9.96K+50.0%12.0K after
Nov 10, 2021 (view filing)Nov 91 daySchambye Hans T.Chief Executive OfficerPPurchase+4.50K$3.50+$15.8K+10.5%47.4K after
Nov 9, 2021 (view filing)Nov 81 dayFreve JonathanChief Financial OfficerPPurchase+3.00K$3.40+$10.2K+60.0%8.00K after
Aug 19, 2021 (view filing)Aug 181 dayFreve JonathanChief Financial OfficerPPurchase+3.00K$3.92+$11.8K+150.0%5.00K after